Testing a blood test for colon cancer in people due for screening colonoscopy
Checks how well a blood test finds colorectal cancer in people aged 45 to 75.
Plain-language title generated from the registry record
Registry title: Colon Cancer Liquid Biopsy Investigation of Methylation-based Biomarkers Evaluation Using Delta-HLD (CLIMBED)
Key facts
- Where
- Mendoza, ArgentinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 45 and 75 years old?
Source: NCT07168876, who can take part
Where in Argentina
- EpiliquidMendoza, ArgentinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Epiliquid Holding, Inc
- Trial code
- NCT07168876
- Record updated
- 11 September 2025
- Original description
CLIMBED (Colon cancer Liquid biopsy Investigation of Methylation-based Biomarkers Evaluation using Delta-HLD) is a non-randomized, observational, cross-sectional clinical validation study designed to assess the performance of Delta-HLD, Epiliquid's proprietary liquid biopsy technology, for colorectal cancer (CRC) detection. The study will evaluate the test performance in an average-risk population for CRC undergoing screening colonoscopy, which will serve as the gold standard reference.Read full original descriptionShow less
Clinical Validation Cross-sectional Study for Colorectal Cancer Assessment Using Delta-HLD Technology (CLIMBED)
CLIMBED (Colon cancer Liquid biopsy Investigation of Methylation-based Biomarkers Evaluation using Delta-HLD) is a non-randomized, observational, cross-sectional clinical validation study designed to assess the performance of Delta-HLD, Epiliquid's proprietary liquid biopsy technology, for colorectal cancer (CRC) detection. The study will evaluate the test performance in an average-risk population for CRC undergoing screening colonoscopy, which will serve as the gold standard reference.
Inclusion: Men and women aged 45-75 years; Indication of colorectal cancer screening colonoscopy by treating physician.
Exclusion: Major trauma, surgery, transfusion in past 30 days; First-degree family history of CRC; Inflammatory bowel disease (ulcerative colitis, Crohn's disease); Other malignancies within 5 years; Known hereditary CRC syndromes (Lynch, FAP); Current participation in an interventional clinical trial.